Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

We Still Have No Vaccine for Covid-19! What About Herd Immunity?

We Still Have No Vaccine for Covid-19! What About Herd Immunity?

Herd immunity is a key concept in outbreak control. Herd immunity means that, for major outbreaks caused by an infectious microorganism to stop, part of the population (for example, 60%) must become immune, either by overcoming natural infection or through vaccination. In the current COVID-19 outbreak, the fundamental question is how, when, and at what cost herd immunity will be achieved.

Herd immunity is achieved when an infected person in a population generates, on average, fewer than one secondary case. In the absence of interventions, this corresponds to the effective reproduction number R0 (that is, the average number of people infected by one case) falling below 1.

Most R0 estimates fall in the range 2.5 - 4, without a clear geographical pattern. R0 =3, as estimated for France, implies an expected herd immunity threshold for SARS-CoV-2 at which 67% of the population develops immunity. Equation 1 also shows that, even without herd immunity, the intensity of social distancing needed to control transmission decreases as population immunity rises. For example, at R0 =3, transmission rates must be reduced by 67% to limit spread if the population is fully susceptible, but only by 50% if one-third of the population is already immune.

The role of superspreaders

Population immunity can sometimes achieve herd immunity before bringing R0 below 1. For example, if some individuals are more likely to become infected and transmit the virus because they have more contacts, these superspreaders (superspreader / super-carrier / super-transmitter: an infected person who transmits an infectious agent to susceptible people far more than expected) are likely to become infected first. Consequently, the proportion of susceptible individuals is rapidly depleted through superspreaders, and transmission slows. However, measuring the effect of this phenomenon in the context of COVID-19 remains difficult. 

R0 =3 was used by Britton and colleagues, who showed that accounting for age-specific contact patterns (for example, people aged >80 have far fewer contacts than those aged 20-40) lowered the herd immunity threshold from 66.7% to 62.5%. If the number of contacts is also assumed to vary substantially among individuals within the same age group, herd immunity could be achieved with only 50% population immunity.

If superspreading is driven by events rather than individuals, or if control measures reduce or change the potential superspreader group, there may be a limited effect on herd immunity. Another factor that could support a lower COVID-19 herd immunity threshold is children's role in viral transmission. Initial reports found that, particularly below the age of 10, children may be less susceptible and infectious than adults; in that case, they could partly be excluded from herd immunity calculations.

Can the population's level of immunity be estimated?

Population immunity is typically estimated through cross-sectional surveys of representative samples using tests that measure humoral immunity (antibody levels): serological tests. Surveys in countries affected early in the COVID-19 outbreak, such as Spain and Italy, show that nationwide antibody (IgG) positivity ranges from 1% to 10%, with peaks in heavily affected urban areas of approximately 10-15%. Interestingly, this is consistent with earlier mathematical model estimates using nationally reported death counts and estimates of the infection fatality rate. 

Some have argued that humoral immunity does not capture the full spectrum of protective immunity against SARS-CoV-2 and that the first outbreak wave produced greater immunity than cross-sectional antibody surveys measured. Indeed, T-cell reactivity has been documented among patients' contacts in the absence of detectable humoral immunity, although the protective nature and duration of the observed response are unknown.

Another unknown is whether preexisting immunity to the common cold, that is, to earlier coronaviruses, might provide some cross-protection. Several studies have reported cross-reactive T cells among individuals susceptible to SARS-CoV-2, comprising 20-50% of those individuals. However, whether these T cells prevent SARS-CoV-2 infection or protect against severe disease has not yet been determined.

Preliminary reports from studies in children indicate that past seasonal coronavirus infections and susceptibility to SARS-CoV-2 infection have no association. Clearly, sterilizing immunity through cross-protection was not seen during the SARS-CoV-2 outbreak on the Charles de Gaulle aircraft carrier, where 70% of young adult sailors became infected before the outbreak stopped.

When will it end?

Taking these considerations into account, there is little evidence that SARS-CoV-2 spread could stop naturally before at least 50% of the population becomes immune. Another question is what would be needed to reach 50% population immunity (immunity to seasonal coronaviruses is generally relatively short-lived). We currently do not know how long naturally acquired immunity to SARS-CoV-2 lasts, especially in people with mild disease, or how many rounds of reinfection may occur before robust immunity develops: this remains unknown. However, evidence shows that antibody levels after Covid-19 infection fall rapidly from month 1 and that people may contract Covid-19 again around month 2. This is an important warning that people should not abandon precautions even if they have had and recovered from the disease.

Nevertheless, reinfection has so far been definitively documented in only a very limited number of cases, and it is unclear whether it is rare or will become common. Similarly, it is unknown how prior infection affects the course of disease on reinfection and whether some preexisting immunity affects viral spread and transmissibility.

What happens in other pandemics?

Influenza pandemics generally achieve herd immunity after two to three waves, each interrupted by interventions such as cross-protection generated by immunity to typical seasonal influenza viruses, and more rarely to previously encountered influenza viruses, together with the help of vaccines when available. With an estimated infection fatality rate of 0.3-1.3%, the cost of achieving COVID-19 herd immunity through natural infection would be very high, particularly without improved patient management and optimal protection for individuals at risk of serious complications.

Assuming an optimistic herd immunity threshold of 50% for countries such as France and the United States, this would mean 100,000–450,000 and 500,000–2,100,000 deaths, respectively. Men, older people, and those with comorbidities are disproportionately affected; infection fatality rates for those over 60 are 3.3%, and people with diabetes, heart disease, chronic respiratory disease, or obesity have increased mortality rates. The expected impact would be much smaller in younger populations.

What is the role of a vaccine?

An effective vaccine offers the safest way to achieve herd immunity. As of September 2020, 11 anti-SARS-CoV-2 vaccines had reached phase III; some may therefore become available in early 2021, but their safety and efficacy have not yet been established. Given that vaccine production and distribution will initially be limited, prioritizing those at high risk of serious morbidity will be important even in communities with high vaccine access. 

Vaccines are particularly suitable for generating herd immunity because distribution can target groups with high exposure to the virus, such as healthcare workers or people in frequent contact with customers. In addition, vaccines may not be as effective in older people, yet deaths can be prevented by targeting the most vulnerable populations first. Vaccines could therefore have a much greater effect than naturally acquired immunity in reducing viral circulation, particularly if naturally acquired protective immunity needs boosting through reinfections (vaccines can provide routine boosts if necessary). Given increasing reports of long-term complications even after mild COVID-19, vaccines are also likely to offer a safer option for people not classified as at risk.

For Northern Hemisphere countries, the coming autumn and winter will be challenging because viral circulation is likely to intensify, as recently observed in the Southern Hemisphere with the return of the cold season. At this stage, only nonpharmacological interventions, such as social distancing, isolation of ill people, face masks, and hand hygiene, have been proven effective in controlling viral circulation and should therefore certainly be implemented.

Potential antiviral drugs that reduce viral loads and thus transmission, or treatments that prevent complications and deaths, may become important for outbreak control in the coming months. These are the options available until vaccines allow us to achieve herd immunity as safely as possible.

Sources

Fontanet, A., Cauchemez, S. COVID-19 herd immunity: where are we?. Nat Rev Immunol 20, 583–584 (2020).

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

We Still Have No Vaccine for Covid-19! What About Herd Immunity?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy